Empagliflozin in lupus mice. Two studies, opposite results: 🔹 Zhao, ARD 2023 🇨🇳: early use ↓proteinuria, ↓anti-dsDNA, improved podocyte autophagy. doi.org/10.1136/ard-... 🔹 Vilardell-Vilà, KI 2025 🇪🇸: no benefit when started during active nephritis. doi.org/10.1016/j.ki...

Dual BLyS/APRIL blockade with telitacicept improved systemic #lupus activity and reduced proteinuria in patients with moderate (and years after #nephritis onset) renal involvement. doi.org/10.1056/nejm...

We uncovered a powerful type I interferon signature in #ANCA #vasculitis, especially in MPA, tied to kidney prognosis, and close to lupus nephritis. 🚀 This opens exciting perspectives for IFN–targeted therapies in vasculitis. Full results presented at #KidneyWk @asnkidney.bsky.social in a few hours!

Groundbreaking work by @tharaux-lenoir-lab.bsky.social: blocking mineralocorticoid receptor signaling in parietal epithelial cells prevents crescentic GN. Shall we stop using methylpred pulses for AAV-GN induction, given their unwanted mineralocorticoid activity? doi.org/10.1016/j.kint.2025.07.037

Using kidney transcriptomics, we identified a robust 12-gene signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology, and opening the way to precision medicine. Thank you for the highlight @asnpublications.bsky.social !

Outstanding review that outlines evolving #ANCA #vasculitis treatments: from B-cell therapies (obinutuzumab, CAR-T) and T-cell therapies (ustekinumab) to new comers (T-cell engagers, alternative-pathway inhibitors, antifibrotics, ANCA–antigen blockers). A must read! www.nature.com/articles/s41...

Ex vivo #CRISPR-Cas9 knock out PR3 autoantigen in HSPCs prevents PR3-ANCA-driven neutrophil activation while preserving immune function. While aHSCT would still be required, this opens the door to sustained, drug-free remission in PR3 #ANCA #vasculitis! doi.org/10.1016/j.ki... @kidneyint.bsky.social

Targeting endothelial ferroptosis protects kidneys in #ANCA -associated #vasculitis, while systemic inhibition increases inflammation. This is why cell-specific therapies should be prioritised over blanket treatments! @kidneyint.bsky.social doi.org/10.1016/j.ki...

This new study shifts the focus from anti-MPO IgG to IgM in #ANCA -associated #vasculitis. IgM autoantibodies not only trigger potent complement activation but also dominate the autoreactive memory B cell pool—revealing a new pathogenic paradigm. Potential implications ⬇️

Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Our analysis from the french REIN registry ⬇️

Last one: IV methylpred in very severe (eGFR<10 ml/min) #ANCA #vasculitis. Retrospective Chinese study, N=106, mostly MPO, high MMF use. IVMP (vs. no): higher dialysis independence (37% vs. 7%) & nearly significant lower mortality (19% vs. 37%, p = .056). bmcnephrol.biomedcentral.com/articles/10....

IV methyl pred in severe (sCr > 500 or dialysis) #ANCA #vasculitis (observ.): no benefit for survival or renal recovery at M12. Higher risks of infections & diabetes with IVMP. Lower doses (1.5g total), more severe patients, MPO/PR3 more balanced than ⬇️. bmcnephrol.biomedcentral.com/articles/10....

IV methylpred in "severe" #ANCA #vasculitis (observational study, target trial emulation): 1.0 g/day reduced 48-week mortality without increasing serious infections. 0.5 g/day showed limited effect. Limits: quite small number of subjects (201), mostly MPO. academic.oup.com/rheumatology...

PEXIVAS post-hoc: no effect of reduced GC dose on kidney recovery in #ANCA #vasculitis. Faster kidney recovery with PLEX but not sustained beyond 3 months (better for subgroup GFR 15-30?). Real PLEX effect vs convection effect? @kronbichlerlab.bsky.social www.kidney-international.org/article/S008...

66% of #ANCA #vasculitis patients have coronary artery calcification (CAC score>0), indicating high cardiovascular risk, especially in MPO+. Only 25% are on statins. Urgent need for better screening and tailored cardiovascular prevention. rmdopen.bmj.com/content/11/1...

Infection is the top cause of death in #ANCA -associated #vasculitis, mostly during remission. Death certificates misreport causes, linking EHRs improves accuracy. We need to reduce infection risks through better immunosuppressive therapies www.sciencedirect.com/science/arti...

In #ANCA #vasculitis, 27% patients rated their health better or worse (≥ 20 PGA points) than their physicians did. This discordance highlights the need to address patients' perspectives to improve communication, shared decision-making, and care outcomes. pubmed.ncbi.nlm.nih.gov/39671122/

This study (aacrjournals.org/cancerimmuno...) shows that, in tumor-bearing mice, C5aR blockade boosts anti-PD1 efficacy by enhancing #antitumor immunity. Could these benefits translate to reducing long-term treatment-related adverse events in our #ANCA #vasculitis patients?

First AI-driven model for grading #ANCA -associated #glomerulonephritis lesions achieves 93% accuracy. Grad-CAM heatmaps align with pathologists’ focus, enhancing prognosis reliability. Bonus: the heatmaps look like colorful PET scans of glomeruli! www.kireports.org/article/S246...

In #ANCA-associated renal #vasculitis, higher percentage of normal glomeruli in kidney biopsy predicts lower rates of ESKD. Maybe good for AI implementation, but… performance vs. standard classifications (Berden, AKRiS) and beyond 1 year unknown. www.kireports.org/article/S246...

Infections affect >50% of #ANCA -associated #vasculitis patients, with risk factors including diabetes, ESKD, kidney/lung involvement and treatment (methylprednisolone pulses, CYC, PLEX). Main site: respiratory system. Early risk management is crucial. doi.org/10.1016/j.au...

Brace yourself, next Vasculitis Workshop is coming! Key dates: ✅ Abstract submission: 28 March - 19 September 2025 ✅ Workshop dates: 21 - 25 February 2026 📍 Melbourne, Australia vasculitis-melbourne2026.com

Abatacept RCT vs placebo (on top of oral GC) in relapsing non severe granulomatosis #GPA #vasculitis (ABROGATE study): non superiority of abatacept. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point (and SAEs). Dr. C. Langford #ACR24 acrabstracts.org/abstract/a-r...

Results of the TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis. ▶️ higher number of relapse at 6 months for the discontinuation group ▶️ but driven by minor relapses and by subgroup not treated but Rituximab. Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)

Reduced GC dose in #ANCA vasculitis: @terrierben.bsky.social confirms PEXIVAS results in real life: no difference in death/ESKD. Larger composite criteria [see table] (that may be discussed) in favor of standard GC dose, especially for RTX patients and severe AKI ard.bmj.com/content/earl...

Welcome in @terrierben.bsky.social. The #vasculitis family is growing here on Bluesky!

20 years after their initial MPA model, Xiao, Falk & Jennette publish a groundbreaking paper (doi.org/10.1016/j.ki...). They introduce 3 new mouse models for #ANCA #vasculitis, using anti-MPO abs with different stimuli to mimic MPA, GPA, and EGPA phenotypes. 🧵1/5

Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers? Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!